Description for medicine or protocol of treatment in detail:
|
90 patients with fibromyalgia syndrome diagnosed in the outpatient and ward of the First Affiliated Hospital of Xi'an Medical College from December 2021 to December 2022 were selected. According to the random number table method, the patients were divided into three groups: 30 cases in stellate ganglion block combined with acupuncture group, 30 cases in stellate ganglion block group and 30 cases in acupuncture group. All subjects were treated with corresponding conventional drugs (such as antidepressants, calcium channel receptor blockers, non steroidal anti-inflammatory drugs or sedatives) according to their own disease characteristics. At admission, the patients were treated with pain visual analogue scale (VAS), modified Fibromyalgia Impact Questionnaire (fiqr), Pittsburgh sleep quality index (PSQI), Hamilton Depression Scale (HAMD), and the duration of morning stiffness, the location and quantity of pain were recorded in detail. At the same time, infrared thermal imaging and heart rate variability were monitored and recorded. The venous blood between elbows was drawn at 7:00 a.m. on an empty stomach on the second day of admission, and the electrolyte, CRP, IL-10, IL-6, IL-8, ACTH, CRH, cortisol, blood glucose, blood lipid (cholesterol, triglyceride) were detected.
|
Exclusion criteria:
|
1. Secondary fibromyalgia syndrome, such as osteoarthritis, rheumatoid arthritis, osteoporosis and other rheumatic diseases;
2. Suffering from malignant tumor, chronic infection, epilepsy, coagulation dysfunction, cognitive and mental abnormalities, or serious heart disease, abnormal liver and kidney function;
3. People who are allergic to local anesthetics and those who have fainted;
4. Pregnant and lactating;
5. The elderly and children over 80 years old;
6. Incomplete information.
|